4D Molecular Therapeutics, Inc. short interest in 2025
In 2025, 4D Molecular Therapeutics, Inc.'s disclosed short interest ran from 9.41% of shares outstanding on 28 Feb 2025 to 12.83% on 31 Dec 2025, a change of +3.42 percentage points. The year's high was 12.83% on 31 Dec 2025 and its low 6.50% on 15 Jul 2025, averaging 8.17% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 11.88 days on 30 Apr 2025. Full history: 4D Molecular Therapeutics, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2025 in figures
- Start of year
- 9.41% (28 Feb 2025)
- End of year
- 12.83% (31 Dec 2025)
- Change
- +3.42 pp
- High
- 12.83% (31 Dec 2025)
- Low
- 6.50% (15 Jul 2025)
- Average
- 8.17%
- Highest days to cover
- 11.88 (30 Apr 2025)
- SEC filings marked
- 10
Every report in 2025
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 28 Feb 2025 | 9.41% | 8.71 | results (8-K), 10-K filed, results (8-K) |
| 14 Mar 2025 | 9.03% | 6.97 | |
| 31 Mar 2025 | 9.08% | 7.16 | |
| 15 Apr 2025 | 9.34% | 5.22 | |
| 30 Apr 2025 | 9.05% | 11.88 | |
| 15 May 2025 | 8.38% | 9.03 | 10-Q filed, results (8-K) |
| 30 May 2025 | 7.81% | 10.97 | |
| 13 Jun 2025 | 7.49% | 7.87 | |
| 30 Jun 2025 | 6.97% | 8.43 | |
| 15 Jul 2025 | 6.50% | 10.90 | |
| 31 Jul 2025 | 6.65% | 8.07 | |
| 15 Aug 2025 | 7.39% | 1.03 | 10-Q filed, results (8-K) |
| 29 Aug 2025 | 7.66% | 6.55 | |
| 15 Sep 2025 | 8.36% | 8.39 | |
| 30 Sep 2025 | 8.00% | 5.76 | |
| 15 Oct 2025 | 7.52% | 5.74 | |
| 31 Oct 2025 | 7.62% | 4.36 | |
| 14 Nov 2025 | 7.67% | 5.03 | results (8-K), 10-Q filed, results (8-K) |
| 28 Nov 2025 | 7.46% | 6.85 | |
| 15 Dec 2025 | 7.43% | 6.33 | |
| 31 Dec 2025 | 12.83% | 5.89 |
See also: 4D Molecular Therapeutics, Inc.'s full history · most shorted US stocks of 2025 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.